Merck stops trials of depression drug

Merck announced it has stopped Phase III trial of its first depression treatment because it did not work as expected. The drug, chemically known as aprepitant, was intended to control levels of a protein fragment in the brain linked to emotion and stress.

View Full Article in:

Philadelphia Inquirer, The · Wall Street Journal (tiered subscription model), The · Financial Times (free content)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC